ArticleCell calcium2019
The CaMKII inhibitor KN93-calmodulin interaction and implications for calmodulin tuning of Na
Open access · greenAbstract read
In one paragraph
Article in Cell calcium, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 52 citations in OpenAlex.
- The disulfonic acid ANDS disrupts ANP32B-p53 interaction to suppress chronic myeloid leukemia.Nature communications · 2026Article
- Synergistic antiarrhythmic mechanism of IJournal of translational medicine · 2025Article
- Calmodulin enhancement of mitochondrial calcium uniporter function in isolated mitochondria.Cell calcium · 2025Article
- Nuclear CaMKII Isoforms as Regulators of Transcription: From Developmental to Pathological Persistence.Medical sciences (Basel, Switzerland) · 2025Review
- Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1 -mutated oral squamous cell carcinoma.Chinese medical journal · 2025Article
- Signalling pathways involved in urotensin II induced ventricular myocyte hypertrophy.PloS one · 2025Article
- Development of nifedipine isosteres: an integrated approach to the design, synthesis, and biological assessment of calcium channel blockers.Frontiers in chemistry · 2025Article
- Site-specific incorporation ofCommunications biology · 2024Article
- Studying CaMKII: Tools and standards.Cell reports · 2024Review
- Design, synthesis andRSC advances · 2023Article
- Human disease-associated calmodulin mutations alter calcineurin function through multiple mechanisms.Cell calcium · 2023Article
- Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Pyrimidine Derivatives as Potential Calcium Channel Blockers.Molecules (Basel, Switzerland) · 2023Article
- NaV1.6 dysregulation within myocardial T-tubules by D96V calmodulin enhances proarrhythmic sodium and calcium mishandling.The Journal of clinical investigation · 2023Article
- Article
- CaMKII as a Therapeutic Target in Cardiovascular Disease.Annual review of pharmacology and toxicology · 2023Review
- Effects and potential mechanism of CaInternational journal of molecular medicine · 2022Article
- Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms.Antioxidants & redox signaling · 2022Review
- Tuning of Liver Sieve: The Interplay between Actin and Myosin Regulatory Light Chain Regulates Fenestration Size and Number in Murine Liver Sinusoidal Endothelial Cells.International journal of molecular sciences · 2022Article
- Dynamics and structural changes of calmodulin upon interaction with the antagonist calmidazolium.BMC biology · 2022Article
- Histone deacetylase 4 and 5 translocation elicited by microsecond pulsed electric field exposure is mediated by kinase activity.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 2 countries.
Christopher N JohnsonCenter for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37240, USA; Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: cn.johnson@vumc.org.
Rekha PattanayekDepartment of Life and Physical Sciences, Fisk University, Nashville, TN 37208, USA.
Franck PotetDepartment of Pharmacology Feinberg School of Medicine, Northwestern University, Chicago IL, 60611, USA.
Robyn T RebbeckDepartment of Biochemistry, Molecular Biology and Biophysics University of Minnesota, Minneapolis, MN 55455, USA.
Daniel J BlackwellCenter for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37240, USA.
Roman NikolaienkoDepartment of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University, Maywood IL, 60153, USA.
Vasco SequeiraDepartment of Translational Science Universitätsklinikum, Würzburg, Germany.
Remy Le MeurDepartment of Biochemistry, Vanderbilt University, Nashville TN 37204, USA.
Przemysław B RadwańskiDorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Jonathan P DavisDorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Aleksey V ZimaDepartment of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University, Maywood IL, 60153, USA.
Razvan L CorneaDepartment of Biochemistry, Molecular Biology and Biophysics University of Minnesota, Minneapolis, MN 55455, USA.
Steven M DamoDepartment of Life and Physical Sciences, Fisk University, Nashville, TN 37208, USA.
Sandor GyörkeDorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Alfred L GeorgeDepartment of Pharmacology Feinberg School of Medicine, Northwestern University, Chicago IL, 60611, USA.
Björn C KnollmannCenter for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37240, USA.
The Ohio State University Wexner Medical Center · USVanderbilt University Medical Center · USFisk University · USLoyola University Chicago · USNorthwestern University · USUniversity of Minnesota · USUniversitätsklinikum Würzburg · DEVanderbilt University · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MPathophysiological Regulation of Cardiac Myocyte RyR ChannelR01HL092097 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Donald M Bers, Robyn T Rebbeck · 2010 to 2026
$9.3MCONTROLLED AND UNCONTROLLABLE CALCIUM RELEASE IN HEARTR01HL063043 · NHLBI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI Sandor Gyorke · 1999 to 2026
$8.6MRyanodine Receptor Channels in Heart FailureR01HL074045 · NHLBI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI GYORKE, SANDOR · 2003 to 2024
$8.2MMOLECULAR BIOPHYSICS TRAINING PROGRAM AT VANDERBILTT32GM008320 · NIGMS · VANDERBILT UNIVERSITY · PI CHAZIN, WALTER J. · 1989 to 2023
$7.9MToward a Mechanism-Based Approach to Treating Cardiac ArrhythmiaR35HL144980 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KNOLLMANN, BJORN C · 2019 to 2025
$7.1MRegulation and Dysregulation of Cardiac EC coupling by CalmodulinR01HL138579 · NHLBI · OHIO STATE UNIVERSITY · PI Jonathan Paul Davis, Sandor Gyorke · 2017 to 2026
$6.1MStructural Dynamics of Cardiac Muscle Calcium ATPase RegulationR01HL139065 · NHLBI · UNIVERSITY OF MINNESOTA · PI Robyn T Rebbeck, David D Thomas · 2020 to 2026
$5.2MNCI NIH HHS P30 CA068485NCRR NIH HHS S10 RR025677NEI NIH HHS P30 EY008126NHLBI NIH HHS F32 HL117612NHLBI NIH HHS K99 HL127299NHLBI NIH HHS R00 HL127299NHLBI NIH HHS R01 HL063043NHLBI NIH HHS R01 HL074045NHLBI NIH HHS R01 HL092097NHLBI NIH HHS R01 HL130231NHLBI NIH HHS R01 HL138539NHLBI NIH HHS R01 HL138579NHLBI NIH HHS R01 HL139065NHLBI NIH HHS R35 HL144980NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIGMS NIH HHS R35 GM118089NIGMS NIH HHS T32 GM008320NINDS NIH HHS T32 NS007491
Abstract
Here we report the structure of the widely utilized calmodulin (CaM)-dependent protein kinase II (CaMKII) inhibitor KN93 bound to the Ca
Indexed as
BenzenesulfonamidesBenzylaminesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 2Calcium SignalingCalmodulinCells, CulturedCrystallography, X-RayHumansMyocytes, CardiacNAV1.5 Voltage-Gated Sodium ChannelPhosphorylationProtein BindingProtein ConformationRyanodineRyanodine Receptor Calcium Release ChannelBenzenesulfonamidesBenzylaminesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 2CALM3 protein, humanCalmodulinKN 93NAV1.5 Voltage-Gated Sodium ChannelRyanodineRyanodine Receptor Calcium Release ChannelSCN5A protein, humanSulfonamidesautocamtide-2-inhibitor peptideCalcium calmodulin dependent kinase type II (CaMKII)Calcium signalingCaMKII inhibitionKN92KN93
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.